Onconetix (ONCO) Total Non-Current Liabilities (2022 - 2026)
Onconetix (ONCO) posted quarterly Total Non-Current Liabilities of $3.1 million for Q1 2026, down 78.47% year-over-year from $14.2 million in Q1 2025, and down 33.2% quarter-over-quarter from $4.6 million in Q4 2025.
Onconetix (ONCO) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Total Non-Current Liabilities for 5 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 78.47% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 78.47% YoY), while the FY2025 annual figure was $4.6 million, down 68.21% from the prior year.
- Total Non-Current Liabilities fell to $3.1 million in Q1 2026 per ONCO's latest filing, from $4.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $23.6 million in Q2 2022 and bottomed at $818148.0 in Q3 2022.
- Historically, Total Non-Current Liabilities has averaged $11.1 million across 5 years, with a median of $12.7 million in 2025.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities soared 463.28% — and 2025, when it tumbled 88.02%.
- Onconetix's Total Non-Current Liabilities stood at $3.9 million in 2022, then jumped by 463.28% to $21.9 million in 2023, then plunged by 34.15% to $14.4 million in 2024, then plunged by 68.21% to $4.6 million in 2025, then tumbled by 33.2% to $3.1 million in 2026.
- Business Quant data shows ONCO's Total Non-Current Liabilities at $3.1 million in Q1 2026, $4.6 million in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 2.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.28 Mn |
| Mar 31, 2026 | 3.06 Mn |
| Dec 31, 2025 | 4.58 Mn |
| Sep 30, 2025 | 2.50 Mn |
| Jun 30, 2025 | 12.71 Mn |
| Mar 31, 2025 | 14.21 Mn |
| Dec 31, 2024 | 14.40 Mn |
| Sep 30, 2024 | 20.87 Mn |
| Dec 31, 2023 | 21.87 Mn |
| Dec 31, 2022 | 3.88 Mn |
| Sep 30, 2022 | 818,148.00 |
| Jun 30, 2022 | 23.63 Mn |